circadian rhythm raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-12-04 and is reviewed periodically as new material appears.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
In 1930 Cecil George Paine, a pathologist at the Royal Infirmary in Sheffield, successfully treated ophthalmia neonatorum, a gonococcal infection in infants, with penicillin (fungal extract) on 25 November 1930. In 1940 the Australian scientist Howard Florey (later Baron Florey) and a team of researchers (Ernst Chain, Edward Abraham, Arthur Duncan Gardner, Norman Heatley, Margaret Jennings, Jean Orr-Ewing and Arthur Gordon Sanders) at the Sir William Dunn School of Pathology of the University of Oxford made progress in making concentrated penicillin from fungal culture broth that showed both in vitro and in vivo bactericidal action. In 1941 they treated a policeman, Albert Alexander, with a severe face infection; his condition improved, but then supplies of penicillin ran out and he died. Subsequently, several other patients were treated successfully. In December 1942, survivors of the Cocoanut Grove fire in Boston, United States, were the first burn patients to be successfully treated with penicillin. The first successful use of pure penicillin was in 1942 when Fleming cured Harry Lambert of an infection of the nervous system (streptococcal meningitis) which would otherwise have been fatal. By that time the Oxford team could produce only a small amount. Florey willingly gave the only available sample to Fleming. Lambert showed improvement from the very next day of the treatment, and was completely cured within a week. Fleming published his clinical trial in The Lancet in 1943.
==== Sen-chan ==== Senichi Enari (江成 仙一, Enari Sen'ichi), also known as "Sen-chan" (センちゃん), is the eccentric, yet calmest and smartest member, of the team, due in part to his ability to think things through and being able to do his best thinking while in a handstand, which he considers his "thinking pose". Sen-chan serves as Deka Green (デカグリーン, Deka Gurīn). The oldest of seven siblings from a poor family, he displays nycto- and claustrophobia after accidentally falling into a well when he was a child. He was subsequently rescued by a policeman, which inspired him to take up police work. Despite his usually calm demeanor, he is said to be scary when angered. He also displays a crush on his teammate Umeko, but avoids showing it publicly. As of the crossover film Mahō Sentai Magiranger vs. Dekaranger, they have moved in together. As Deka Green, Sen-chan wields the D-Knuckle and D-Rod, which can combine to form the D-Blaster (ディーブラスター, Dī Burasutā) rifle. He also shares riding the Machine Bull (マシンブル, Mashin Buru) police car with Umeko. Using the D-Rod, Sen-chan can perform the Green Crash (グリーンクラッシュ, Gurīn Kurasshu) attack. Sen-chan is portrayed by Yousuke Itou (伊藤 陽佑, Itō Yōsuke). As a child, he is portrayed by Kengo Tajima (田島 健吾, Tajima Kengo).
Alongside promotions of general law enforcement and upgrades to courts, the package also provided funding for strengthening the PET's activities in the North Atlantic, and provided new maritime equipment to Greenlandic and Faroese police in response to the crisis. By 19 January 2026, a total of over kr. 88 billion (US$13.7 billion) had been committed to "strengthen defense and security in the Arctic", with kr. 29 billion allocated to acquiring F-35 fighter jets alone, and kr. 27.8 billion for anti-aircraft warfare, according to the Ministry of Defence, and at that point Denmark had sent 200 additional soldiers to Greenland. On the same day, more soldiers together with the Chief of the Royal Danish Army, General Peter Harling Boysen, started arriving in Greenland, and Denmark announced that a "substantial contribution" of its armed forces would be sent there. Also on 19 January, Defence Minister Troels Lund Poulsen and Greenlandic Minister of Foreign Affairs Vivian Motzfeldt met NATO secretary general Rutte and their Nordic Security ministers in Brussels about the situation in Greenland. General Boysen said he is ready to defend Greenland. According to Boysen, the soldiers landed in Kangerlussuaq in western Greenland. On 20 January 2026, Denmark deployed additional troops to Greenland, sending dozens of soldiers and senior military leadership to the Arctic territory to reinforce its presence and participate in ongoing multinational exercises, increasing the Danish Armed Forces' personnel stationed there amid heightened international tensions.
Typhoidal Salmonellae induce their own phagocytosis by host macrophages in vivo and inhibit digestion by lysosomal action, thereby using macrophages for their own replication and causing macrophage apoptosis. Macrophages are capable of engulfing and digesting many bacteria during their life. They can die eventually due to factors including pathogenic cytotoxicity, oxidative stress, and phagocytosis-induced apoptosis. Phagocytosis-induced apoptosis results from the powerful apoptotic stimulus of consuming bacteria and is observed in (at least) macrophages and neutrophils.
Sources: en.wikipedia.org
2,5-Dimethoxy-4-propylamphetamine (DOPR) is a psychedelic drug of the phenethylamine, amphetamine, and DOx families related to DOM. It is the derivative of DOM in which the methyl group at the 4 position has been replaced with a propyl group. The drug is taken orally. The drug acts as a serotonin receptor agonist, including of the serotonin 5-HT2A receptor. It produces psychedelic-like effects in animals. DOPR was first described in the literature by Alexander Shulgin in 1970. Subsequently, it was described in greater detail by Shulgin in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved).
== Cracked heels == Cracked heels is a common health problem and it may cause diseases and infections. It is caused by dryness of the foot skin, and accumulation of dead skin. Over time, it may cause pain and irritations. Various moisturising creams and foot files are available to cure and prevent it.
== Mechanisms == Follistatin is an endogenous protein that negatively regulates myostatin. Reduction of myostatin expression is one of the mechanisms for the effects of androgens in promoting muscle growth. Androgens both regulate myostatin expression directly and upregulate follistatin expression. YK-11, a selective androgen receptor modulator, is also a myostatin inhibitor. Resistance training reduces myostatin activity and increases follistatin activity. Pharmacological myostatin inhibitors can therefore be considered exercise mimetics. Creatine, a popular workout supplement, has shown some myostatin inhibitory effects in preclinical studies. Many drugs in development as myostatin inhibitors also reduce the activity of related proteins such as GDF11, activins, and bone morphogenetic proteins. While this off target activity can increase their effectiveness in promoting anabolism, it also increases the risk of adverse effects. Monoclonal antibodies have been developed that disable myostatin, including apitegromab, domagrozumab, landogrozumab, and stamulumab. Another form of myostatin inhibition is gene therapy. Another monoclonal antibody, bimagrumab, works as an antagonist of the ACVR2 and ACVR2B receptors, preventing myostatin and activin A from binding. Because activin A reduces erythropoiesis, targeting the ACVR receptors and inhibiting activin A activity can increase the risk of venous thromboembolism in patients who are not anemic.
=== Novel technologies and mechanisms of cognitive function === Technologies for imaging brain activity The Sur laboratory developed high resolution two-photon microscopy in the intact mouse brain to show that synapses on visual cortex pyramidal neurons are highly dynamic structures whose form and function can change under the influence of electrical activity. They have continued to develop advanced multi-photon technologies for imaging the calcium activity of cells and their processes across multiple cortical areas and depths. Mechanisms of learning and cognition Combined with cell- and projection-specific manipulations, high-density recordings and computational analyses, these technologies have demonstrated principles of information representation, decisions and action selection in higher (parietal and prefrontal) cortex in mice performing perceptual discrimination and memory-guided decision tasks. The lab has elucidated distinct roles of prefrontal cortex subregions that provide feedback to V1 across behavioral states, demonstrating exquisite specificity of top-down projections in cortical networks. The lab is opening up new ways to address longstanding questions about the neural architecture of cognition. For example, they have shown that pulvinar inputs to prefrontal cortex encode sensory history as a low-dimensional activity manifold that forms a substrate for attention, and modular subsets of prefrontal cortex neurons representing specific functions are computationally recombined across tasks to generate flexible behavior.
Although the exact reason these proteins become targets of the immune system is not completely understood, they are thought to become exposed during inflammation or other changes within the cell. Once immune tolerance is lost, B lymphocytes produce anti-U1 RNP antibodies that recognize components of the U1 snRNP complex. While these antibodies are primarily used as biomarkers for autoimmune disease, studies continue to investigate whether they also contribute to inflammation and disease progression.
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.